Sec Form 3 Filing - Jerel Davis @ Turnstone Biologics Corp. - 2023-07-20

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Jerel Davis 2. Issuer Name and Ticker or Trading Symbol Turnstone Biologics Corp. [ TSBX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300 3. Date of Earliest Transaction (MM/DD/YY) 07/20/2023 (Street) LA JOLLA, CA92037 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 988,832 I By Versant Venture Capital V, L.P. ( 2 ) Series A Preferred Stock ( 1 ) < /td> ( 1 ) ( 1 ) Common Stock 75,255 I By Versant Venture Capital V (Canada) LP ( 3 ) Series A Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 32,971 I By Versant Ophthalmic Affiliates Fund I, L.P. ( 4 ) Series A Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 29,744 I By Versant Affiliates Fund V, L.P. ( 5 ) Series B-1 Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 442,055 I By Versant Venture Capital V, L.P. ( 2 ) Series B-1 Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 33,642 I By Versant Venture Capital V (Canada) LP ( 3 ) Series B-1 Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 14,739 I By Versant Ophthalmic Affiliates Fund I, L.P. ( 4 ) Series B-1 Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 13,297 I By Versant Affiliates Fund V, L.P. ( 5 ) Series B-2 Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 957,787 I By Versant Venture Capital V, L.P. ( 2 ) Series B-2 Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 72,892 I By Versant Venture Capital V (Canada) LP ( 3 ) Series B-2 Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 31,936 I By Versant Ophthalmic Affiliates Fund I, L.P. ( 4 ) Series B-2 Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 28,810 I By Versant Affiliates Fund V, L.P. ( 5 ) Series C Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 140,190 I By Versant Venture Capital V, L.P. ( 2 ) Series C Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 10,669 I By Versant Venture Capital V (Canada) LP ( 3 ) Series C Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 4,667 I By Versant Ophthalmic Affiliates Fund I, L.P. ( 4 ) Series C Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 4,216 I By Versant Affiliates Fund V, L.P. ( 5 ) Series D Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 274,990 I By Versant Vantage II, L.P. ( 6 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Jerel Davis C/O TURNSTONE BIOLOGICS CORP. 9310 ATHENA CIRCLE, SUITE 300 LA JOLLA, CA92037 X X Signatures /s/ P. Joseph Campisi, Jr., Attorney-in-Fact 07/20/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock will automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date. ( 2 )Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. ( 3 )Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. ( 4 )Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. ( 5 )Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. ( 6 )Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.